← Back to Search

Behavioral Intervention

Behavioral Intervention for Recurrent Ovarian Cancer

N/A

Waitlist Available

Led By Megan J. Shen, PhD

Research Sponsored by Fred Hutchinson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 years of age or older

Current diagnosis of recurrent epithelial ovarian cancer (regardless of the amount of time since the diagnosis, given the poor prognosis of this illness with a median survival time of less than 2 years)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 35 days

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking at a program called HOPE to see if it can help ovarian cancer patients who have experienced a recurrence of their cancer. Patients with recurrent ovarian cancer often face increased risk of death and

Who is the study for?

The HOPE trial is for patients with recurrent ovarian cancer who are experiencing high levels of distress and reduced quality of life. It aims to help them cope better with their illness.

What is being tested?

This study tests the 'Helping Ovarian Cancer Patients Cope' (HOPE) intervention against usual care, focusing on reducing feelings of hopelessness and helplessness in these patients.

What are the potential side effects?

Since this trial involves behavioral interventions, surveys, record reviews, and interviews rather than medication or invasive procedures, side effects may include emotional discomfort or fatigue from participation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have recurrent ovarian cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at the time of enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at the time of enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and at the time of enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability of the HOPE intervention (Aim 1)

Accrual rates (Aim 1)

Fidelity rates (Aim 1)

+3 more

Secondary study objectives

Acceptability of the HOPE intervention (Aim 2)

Accrual rates (Aim 2)

Completion of advance care directives (Aim 2)

+7 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Aim 2, Group I (HOPE intervention workshop)Experimental Treatment3 Interventions

Patients complete the HOPE intervention workshop either virtually or in person, with three weekly sessions, each lasting 60 to 90 minutes.

Group II: Aim 1 (HOPE intervention workshop, survey, interview)Experimental Treatment4 Interventions

Patients complete the HOPE intervention workshop virtually or in person. The workshop consists of three weekly sessions, each lasting 60 to 90 minutes, along with a survey and an interview for HOPE Intervention refinement during follow up.

Group III: Aim 2, Group II (usual care)Active Control2 Interventions

Patients receive usual care on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Behavioral Intervention

2021

Completed Phase 4

~3740

0 / 2Eligibility criteria met